Skip to main content
ACR Convergence 2025 Main banner
Final Program


Schedule at a Glance
Legend
Presentation Icons
CME
CME
Non-CME
Non-CME
In Person
In Person
On Demand
On Demand
Live Stream
Live Stream
Active Learning
Active Learning
Choose Rheum
Choose Rheum
Emerging Investigator Awardee
Emerging Investigator Awardee

  1. Home

  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    Spondyloarthritis Including Psoriatic Arthritis – Basic Science Poster
    Location: Hall F1
     CE: 0.00
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster I
    Location: Hall F1
     CE: 0.00
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I
    Location: Hall F1
     CE: 0.00
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0535: Comparing Perspectives of Physician-Assessed and Self-Reported Inflammatory Back Pain: Insights from the SHERPAS Cohort
    Location: Hall F1
    Abstract Poster Presenter: Diego Benavent, MD, PhD – Hospital Universitari de Bellvitge
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0554: Real world experience with generic Tofacitinib in Axial Spondyloarthritis from North India
    Location: Hall F1
    Abstract Poster Presenter: Akanksha Kapoor, MD, MBBS (she/her/hers) – Bharati Vidyapeeth Medical College
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0555: Phase 3 Results From an Innovative Trial Design of Treating Plaque Psoriasis Involving Difficult-to-Treat, High-Impact Sites With Icotrokinra, a Targeted Oral Peptide That Selectively Inhibits the IL-23–Receptor
    Location: Hall F1
    Abstract Poster Presenter: Joseph Merola, MD, MSc, FACR, FAAD – UT Southwestern Medical Center
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0556: Evaluating the Efficacy of Sulfasalazine Compared to Placebo in the Treatment of Psoriatic Arthritis in Adults: A Systematic Review and Meta-Analysis
    Location: Hall F1
    Abstract Poster Presenter: Khadija Mohib, MD – Kirk Kerkorian School of Medicine at UNLV
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0557: Efficacy of Upadacitinib in Male and Female Patients with PsA: Results from the SELECT-PsA 1 and 2 Trials
    Location: Hall F1
    Abstract Poster Presenter: Lucia Novelli, MD – AbbVie
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0558: Early Systemic and Skin Pharmacodynamic Effects of Icotrokinra in Participants with Moderate-to-Severe Plaque Psoriasis: Results Through Week 24 of the Phase 3, ICONIC-LEAD Study
    Location: Hall F1
    Abstract Poster Presenter: Monica Leung, n/a – Johnson & Johnson, San Diego, CA, USA
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0559: Impact of Secukinumab on Cardiovascular Disease in Patients with Psoriasis, PsA, and Axial Spondyloarthritis: A Systematic Review of Existing Evidence
    Location: Hall F1
    Abstract Poster Presenter: Nehal Mehta, MD MSCE – The George Washington University School of Medicine and Health Sciences
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0560: Single Cell Sequencing Analysis of Tumour Necrosis Factor Inhibitor Drug Response Reveals Enrichment of Pro-inflammatory Pathway in Non-responders and Amino Acid Metabolic Pathways in Responders
    Location: Hall F1
    Abstract Poster Presenter: Phuong Nguyen, BSc – University of Toronto
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0561: Patient Characteristics and Treatment Patterns of Traditional and Advanced Therapies Prior to First Secukinumab Intravenous (IV) Administration in Patients with Spondyloarthritis (SpA) in US Real-World Clinical Settings
    Location: Hall F1
    Abstract Poster Presenter: Alan Kivitz, MD, MACR – Altoona Center for Clinical Research
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0562: Icotrokinra (ICO), a Novel Targeted Oral Peptide, in Patients (Pts) With Psoriatic Disease: Exploratory Assessments From a Phase 2 Psoriasis (PsO) Study Informing a Phase 3 Clinical Program in Psoriatic Arthritis (PsA)
    Location: Hall F1
    Abstract Poster Presenter: Alexis Ogdie, MD – University of Pennsylvania
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0563: Efficacy and Safety of Guselkumab in Patients with Active Psoriatic Arthritis and Inadequate Response and/or Intolerance to One Prior Tumor Necrosis Factor Inhibitor
    Location: Hall F1
    Abstract Poster Presenter: Alexis Ogdie, MD – University of Pennsylvania
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0564: Improvements in Patient Reported Outcomes Through 24 Weeks of Guselkumab Treatment in Participants with Active Psoriatic Arthritis and Inadequate Response and/or Intolerance to One Prior Tumor Necrosis Factor Inhibitor
    Location: Hall F1
    Abstract Poster Presenter: Alice Gottlieb, MD, PhD – Icahn School of Medicine at Mount Sinai
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0565: Combination of Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis: A Case-Series
    Location: Hall F1
    Abstract Poster Presenter: Andre Lucas Ribeiro (he/him/his) – Universidade Federal do Rio Grande do Sul
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0566: Predictor Risk Factors For Developing Difficult-to-Treat Psoriatic Arthritis in Patients Initiating a First bDMARD: a Binational Study
    Location: Hall F1
    Abstract Poster Presenter: Astrid Goudot, MD – Université de Lille
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0567: Sonelokimab in Biologic-Experienced Patients With Active Psoriatic Arthritis: Results From a Phase 2 Trial (ARGO) and Study Design of a Phase 3 Trial (IZAR-2) in Patients With Inadequate Response or Intolerance to Biologic TNFi, Including a Risankizumab Reference Arm
    Location: Hall F1
    Abstract Poster Presenter: Atul Deodhar, MD – Oregon Health & Science University
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0568: Drug-Free Remission in Early Peripheral Spondyloarthritis: 10-year follow-up from the CRESPA-trial
    Location: Hall F1
    Abstract Poster Presenter: Caroline Damen, MD – UZ Gent
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0569: ASAS Recommendations on Reporting Outcomes of Core Outcome Set Instruments in Axial Spondyloarthritis Clinical Trials
    Location: Hall F1
    Abstract Poster Presenter: Floris van Gaalen, MD – LUMC
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0570: Phyto- and Endo-cannabinoids Exhibit Ex Vivo Anti-Inflammatory Effects in Refractory Rheumatic inflammatory/Autoimmune Patients: Toward Personalized Cannabinoid Therapy
    Location: Hall F1
    Abstract Poster Presenter: Gilad Halpert, PhD – Reichman University
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0571: Single-cell RNA Sequencing Highlights the Role of Innate Immunity in Identifying Candidates for Early Biologics Treatment in Axial Spondyloarthritis
    Location: Hall F1
    Abstract Poster Presenter: Jaejoon Lee, MD;PhD – Samsung Medical Center, Sungkyunkwan University School of Medicine
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0572: Real-World Treat-to-Target Strategy in Psoriatic Arthritis: 48-week Results from the MONITOR-PsA Cohort
    Location: Hall F1
    Abstract Poster Presenter: Jean-Guillaume Letarouilly, PhD, MD – CHU Lille
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0573: Effects of Sonelokimab, an IL-17A- and IL-17F-Inhibiting Nanobody, on Patient-Reported Symptoms and Quality of Life in Psoriatic Arthritis: Results From the Randomized, Double-Blind, Placebo-Controlled Phase 2 ARGO Trial
    Location: Hall F1
    Abstract Poster Presenter: Joseph Merola, MD, MSc, FACR, FAAD – UT Southwestern Medical Center
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0574: Bimekizumab 3-Year Efficacy In Patients With Psoriasis And Risk Factors For Progression To Psoriatic Arthritis Or Screening Positive For Psoriatic Arthritis: Long-Term Results From Five Phase 3/3b Trials
    Location: Hall F1
    Abstract Poster Presenter: Joseph Merola, MD, MSc, FACR, FAAD – UT Southwestern Medical Center
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0575: Why Do Some Psoriatic Arthritis Patients Fail Treatment? Exploring the Profile of D2T Patients
    Location: Hall F1
    Abstract Poster Presenter: Laia de Daniel Bisbe, -None- – Hospital Universitari de Bellvitge
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0576: Factors impacting progression from oligoarticular to polyarticular PsA: Data from the FOREMOST study
    Location: Hall F1
    Abstract Poster Presenter: Laura Coates, MD, PhD – University of Oxford
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0577: Persistence and Effectiveness Across PsA Patient Subgroups with Guselkumab and IL-17 Inhibitors: 6-Month Results of the PsABIOnd Observational Study
    Location: Hall F1
    Abstract Poster Presenter: Laure Gossec, MD;PhD – Sorbonne Universite and Pitie-Salpetriere Hospital
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0578: Real-world Effectiveness of Upadacitinib on Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Core Domains for Patients with Psoriatic Arthritis: Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
    Location: Hall F1
    Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0579: Characteristics and Treatment Patterns among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating a Third or Higher Line of Biologic or Targeted Disease-Modifying Antirheumatic Drug Therapy
    Location: Hall F1
    Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0580: Persistence and Disease Activity Control among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating a Third or Higher Line of Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy
    Location: Hall F1
    Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0581: Effects of Apremilast on Body Mass Index, Weight, and HbA1c as Cardiometabolic Outcomes in Patients With Early Oligoarticular Psoriatic Arthritis in the FOREMOST Study
    Location: Hall F1
    Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0582: Long-Term Efficacy and Safety of Tofacitinib in Active Axial Spondyloarthritis: Experience from a Tertiary Care Center in South India
    Location: Hall F1
    Abstract Poster Presenter: Prabhu Vasantha Kumar, MD, DM – GKNM Hospitals & Research Institute, Coimbatore, Tamil Nadu, India
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0583: Baseline Peripheral Phenotypes Are Associated with Differential Response to TNF Inhibitors in Psoriatic Arthritis. A Cluster Analysis Approach
    Location: Hall F1
    Abstract Poster Presenter: Raquel Granados, MD – Hospital Universitario Reina Sofia
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0584: Difficult-to-Manage Axial Spondyloarthritis According to ASAS Criteria in Reuma-Check Cohort: Frequency, Predictive Factors, and Treatment Patterns.
    Location: Hall F1
    Abstract Poster Presenter: Rodrigo Garcia Salinas, MD – Hospital Italiano La Plata
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0585: Fungal Infections, Including Candida, in Patients With Active Axial Spondyloarthritis Treated With Secukinumab: A Pooled Analysis of 10 Phase 3 Trials
    Location: Hall F1
    Abstract Poster Presenter: Shikha Singla, MD – MCW
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0586: Immune Checkpoint agonists: A New horizon for treatment of psoriatic arthritis
    Location: Hall F1
    Abstract Poster Presenter: Siba Raychaudhuri, MD – UC Davis, School of Medicine/ VA Medical Center, Sacramento
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0587: Regulatory Role of IL­17 F in the Pannus Formation of Psoriatic Arthritis: A Comparative Study with IL-17A
    Location: Hall F1
    Abstract Poster Presenter: Siba Raychaudhuri, MD – UC Davis, School of Medicine/ VA Medical Center, Sacramento
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0588: The effect of biological and targeted synthetic DMARDs on peripheral manifestations in axial spondyloarthritis: a systematic literature review
    Location: Hall F1
    Abstract Poster Presenter: Sofia Ramiro, MD, PhD – Leiden University Medical Center
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0589: Comparing Efficacy of Upadacitinib in Male and Female Patients with axSpA: Results from the SELECT-AXIS 1 and 2 Trials
    Location: Hall F1
    Abstract Poster Presenter: Sofia Ramiro, MD, PhD – Leiden University Medical Center
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0590: Effect of Deucravacitinib Treatment on Disease Activity–Associated Plasma Biomarkers in Patients With Active Psoriatic Arthritis: Results From 2 Phase 3 Studies
    Location: Hall F1
    Abstract Poster Presenter: Vinod Chandran, MD, PhD, MBBS, DM, FRCPC – University of Toronto
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0591: An Interim Analysis of Health-related Quality of Life Outcomes from an International Multicentre Observational Study in Patients with Psoriatic Arthritis Initiating Bimekizumab in Real-world Clinical Practice
    Location: Hall F1
    Abstract Poster Presenter: Xenofon Baraliakos, MD – Rheumazentrum Ruhrgebiet
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0592: An Interim Analysis of Health-related Quality of Life Outcomes from an International Multicentre Observational Study in Patients with Axial Spondyloarthritis Initiating Bimekizumab in Real-world Clinical Practice
    Location: Hall F1
    Abstract Poster Presenter: Xenofon Baraliakos, MD – Rheumazentrum Ruhrgebiet
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0110: SKG Mice Develop CD4⁺ T Cell–Driven Psoriasis and Enable Study of Endogenous Antigen-Specific Responses
    Location: Hall F1
    Abstract Poster Presenter: Judith Ashouri-Sinha, MD (she/her/hers) – University of California, San Francisco
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0111: Predicting Response To Adalimumab In Patients With Psoriatic Arthritis Using Epigenetic Chromosome Conformation Signatures
    Location: Hall F1
    Abstract Poster Presenter: Patricia Riedlova, PhD – University of Glasgow
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0553: Modified A-Tool: An online self-screening tool for axial spondyloarthritis for patients with chronic back pain
    Location: Hall F1
    Abstract Poster Presenter: Zeyu Tang, MD – Yale School of Medicine
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0538: Development of an Artificial Intelligence Tool for Lesion Detection in Axial Spondyloarthritis patients with Active Sacroiliitis on Magnetic Resonance Imaging
    Location: Hall F1
    Abstract Poster Presenter: Khalid Al Naqbi, MD, MSc, CCD, FRCPC, FACP, FACR (he/him/his) – Sheikh Tahnoon Medical City
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0524: Radiographic progression in sacroiliac joints in five years follow up in non-radiographic axial spondyloarthritis patients and the predictive factors
    Location: Hall F1
    Abstract Poster Presenter: Servet Akar, MD – Izmir Katip Çelebi University School of Medicine
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0530: Evaluating ChatGPT's Performance in Diagnosing Low Back Pain: A Comparison with Clinicians and Impact of Prompted Specialties
    Location: Hall F1
    Abstract Poster Presenter: Annika Nack, MD – Hospital Germans Trias i Pujol
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0545: Temporal trends in the phenotype and treatment outcomes in axial spondyloarthritis patients included in randomized clinical trials over 25 years: a systematic literature review and meta-regression analysis
    Location: Hall F1
    Abstract Poster Presenter: Omar-Javier Calixto, MD – Rheumazentrum Ruhrgebiet
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0532: Generative artificial intelligence provides synthetic data to discriminate patients with seronegative rheumatoid arthritis versus psoriatic arthritis sine psoriasis
    Location: Hall F1
    Abstract Poster Presenter: Antonio Tonutti, MD – Humanitas University
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0540: Low-Dose CT reveals syndesmophyte progression in axial SpA, particularly in the thoracic spine: Insights from the SPACE cohort covering early and established disease
    Location: Hall F1
    Abstract Poster Presenter: Manouk de Hooge, PhD – Ghent University Hospital & Leiden University Medical Center
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0544: Prevalence and Baseline Characteristics associated with Difficult-to-Manage Axial Spondyloarthritis in the DESIR Cohort
    Location: Hall F1
    Abstract Poster Presenter: Olivier Fakih, MD, MPH – CHU Besançon
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0547: Determinants of Difficult-to-Manage Axial Spondyloarthritis: Results from a Prospective Cohort Study
    Location: Hall F1
    Abstract Poster Presenter: Patricia Remalante-Rayco, MD, MSc – University Health Network
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0552: Radiographic Sacroiliitis Progression in Psoriatic Arthritis
    Location: Hall F1
    Abstract Poster Presenter: Virginia Carrizo Abarza, Sr, MD – Toronto Western Hospital - University of Toronto
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0100: Therapeutic Modulation of NAD+ Metabolism in Inflammatory Rheumatic Disorders by TNFi and NAD+ Precursors
    Location: Hall F1
    Abstract Poster Presenter: Beatriz Vellón-García, MSc – Department of Cell Biology, Physiology and Immunology, Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, Cordoba, Spain.
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0109: Application of Psoriatic Arthritis Mouse Models in Preclinical Pharmacodynamic Evaluation
    Location: Hall F1
    Abstract Poster Presenter: Juan Liang, DrPH – Gempharmatech
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0523: SPECTREM: Guselkumab Significantly Improves Patient Reported Outcomes at Week 16 in Participants with Low Body Surface Area, Moderate Psoriasis with Special Sites Involvement
    Location: Hall F1
    Abstract Poster Presenter: Linda Hou, PhD, DDS – JNJ Innovative Medicine
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0541: Inflammatory Back Pain Is Not Associated With HLA-B27 Positivity or CRP Levels in a Nationally Representative U.S. Population
    Location: Hall F1
    Abstract Poster Presenter: Mark Hwang, MD,MS – UTHealth Houston
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0550: Clinical and Genetic Factors Associated with Anti-TNF Therapy Initiation in Radiographic Axial Spondyloarthritis: A 15-Year Observational Study
    Location: Hall F1
    Abstract Poster Presenter: Tae-jong Kim, MD, PhD – Department of Rheumatology, Chonnam National University Medical School and Hospital
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0525: Cost-of-Illness Among Newly Diagnosed Patients with Psoriatic Arthritis in Sweden
    Location: Hall F1
    Abstract Poster Presenter: Tor Olofsson, MD, PhD – Lund University, Skåne University Hosptital
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0543: Unveiling Sacroiliac Joint Involvement in Psoriatic Arthritis: MRI, Radiographic, and Clinical Insights from 581 European Routine Care Patients
    Location: Hall F1
    Abstract Poster Presenter: Nora Vladimirova, MD, PhD (she/her/hers) – Rigshospitalet-Glostrup
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0549: High Prevalence of Obstructive Sleep Apnea in Psoriatic Arthritis: A Polysomnography-Based Cross-Sectional Study
    Location: Hall F1
    Abstract Poster Presenter: Suzan Attar, MD, FRCPC, FACR – King Abdulaziz University
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0536: Can achieving sustained low disease activity through treat-to-target management arrest enthesiophyte progression in psoriatic arthritis? A two-year prospective study using high resolution peripheral quantitative computed tomography
    Location: Hall F1
    Abstract Poster Presenter: Isaac Cheng, PhD – The Chinese University of Hong Kong
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0522: The Incidence Rate and Risk Factors of Arrhythmias in Patients with Psoriatic Arthritis
    Location: Hall F1
    Abstract Poster Presenter: Lihi Eder, MD, PhD – University of Toronto
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0539: Which instrument measuring structural damage progression in axial SpA is most sensitive to change? Analyses from the SPondyloArthritis Caught Early cohort
    Location: Hall F1
    Abstract Poster Presenter: Liese de Bruin, MSc – Leiden University Medical Center
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0528: Apolipoprotein A1 and B Levels Indicate Specific Lipid Changes in Early Treatment Naïve Psoriatic Arthritis and Correlate with 1-year Disease Activity
    Location: Hall F1
    Abstract Poster Presenter: Alla Ishchenko, MD (she/her/hers) – ZAS Antwerpen
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0102: Iron Metabolism Dysregulation and Inflammation in Ankylosing Spondylitis: Role of SLC39A14 in Extracellular Matrix Remodeling
    Location: Hall F1
    Abstract Poster Presenter: Dachun Zhuo, n/a – Fudan University
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0106: Investigation of DNA Methylation Inhibition in a Mouse Model of Ankylosing Spondylitis
    Location: Hall F1
    Abstract Poster Presenter: HOSHIKO FURUSAWA, -None- – juntendo
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0533: Reactive Arthritis Transcriptomics: Enriched Enterobacteriaceae-related Pathways in Synovial Fluid and in Blood is Associated with Drug-free Remission
    Location: Hall F1
    Abstract Poster Presenter: Avarna Agarwal, MD (she/her/hers) – Department of Clinical Immunology and Rheumatology, Kalinga Institute of Medical Sciences, Bhubaneswar, Odisha
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0537: HLA-B27 and Axial Involvement as Independent Risk Factors for Uveitis in Spondyloarthritis: New Insights from a 15-Year Real-Life Study
    Location: Hall F1
    Abstract Poster Presenter: Kent LE, MD (he/him/his) – Jean Monnet University
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0546: Multimorbidity clusters in psoriatic arthritis, psoriasis, and axial spondyloarthritis and their association with healthcare utilization: A population-based study
    Location: Hall F1
    Abstract Poster Presenter: Paras Karmacharya, MD, MS – Vanderbilt University, Nashville, TN
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0534: Prevalence and Impact of Fibromyalgia on Disease Outcomes and Treatment in Axial Spondyloarthritis: 10-year Follow-up Data From the DESIR Cohort
    Location: Hall F1
    Abstract Poster Presenter: Clementina Lopez-Medina, MD, PhD (she/her/hers) – Reina Sofia University Hospital
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0527: Gaps in Documentation of Psoriatic Arthritis Domains in General Rheumatologic Practices Compared to Rheumatology-dermatology Combined Clinics
    Location: Hall F1
    Abstract Poster Presenter: Alexandra Rice, BS (she/her/hers) – NYU Grossman School of Medicine
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0531: Evaluating the Diagnostic Utility of 14-3-3 eta Autoantibodies in Axial Spondyloarthritis: A Multiplex Assay Approach
    Location: Hall F1
    Abstract Poster Presenter: Anthony Marotta, PhD (he/him/his) – Augurex Life Sciences Corp
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0112: Proteome-wide Mendelian Randomization Identifies Therapeutic Targets in Psoriatic Arthritis
    Location: Hall F1
    Abstract Poster Presenter: Proton Rahman, MD – Memorial University
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0114: A Rare Variant in the extl3 Gene Is Associated with Altered Wnt Signaling Pathway in a Novel Mouse Model of Axial Spondyloarthritis
    Location: Hall F1
    Abstract Poster Presenter: Stéphane HILLIQUIN, n/a – Département de Rhumatologie, Hôpital Cochin, Assistance publique des Hôpitaux de Paris, Université Paris-Cité, Paris, France
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0542: Transition from Psoriasis to Psoriatic Arthritis: Does Family History Influence the Time to Onset of Arthritis in Psoriasis Patients?
    Location: Hall F1
    Abstract Poster Presenter: Marta Flores, MD – University of Cordoba
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0103: Common and Rare Variant Contributions to Familial Aggregation in Spondyloarthritis
    Location: Hall F1
    Abstract Poster Presenter: Félicie Costantino, MD, PhD – AP-HP
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0108: In Vivo and In Vitro Analysis of IL-23 Modulation Following Anti-TNF Therapy in Psoriatic Arthritis
    Location: Hall F1
    Abstract Poster Presenter: Jesús Eduardo Martín Salazar, MSc – University of Córdoba
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0104: Dissecting the Genetic and Functional Association of CARD9 with Axial Spondyloarthritis
    Location: Hall F1
    Abstract Poster Presenter: Félicie Costantino, MD, PhD – AP-HP
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0113: ZEB2 and MLCK1 may impair gut barrier integrity in MIF-Deficient SKG Mice
    Location: Hall F1
    Abstract Poster Presenter: Shaghayegh Foroozan Boroojeni, MSc – University Health Network/University of Toronto
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0529: Anti-peptidylarginine deiminase-2 (anti-PAD2) Autoantibodies in Psoriatic Arthritis
    Location: Hall F1
    Abstract Poster Presenter: Ana-Maria Orbai, MD, MHS – Johns Hopkins University School of Medicine, Division of Rheumatology
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0098: The Deubiquitinase TRABID is a Regulator of Osteogenesis and Inflammation in Spondyloarthritis:
    Location: Hall F1
    Abstract Poster Presenter: Archita Srinath, BSc;MSc – University of Toronto
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0099: Time course and impact of  IL17A on hepatic inflammation and fibrosis in adjuvant induced arthritis
    Location: Hall F1
    Abstract Poster Presenter: Arthur Dollinger, n/a (he/him/his) – CHU Besancon
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0526: Identification of Urine Proteomic Biomarkers Associated with Ankylosing Spondylitis
    Location: Hall F1
    Abstract Poster Presenter: Yoon-Jeong Oh, MD – Uijeongbu Eulji Medical Center
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0105: Inflammatory Cytokines, Matrix Metalloproteinases and Bone Markers Expressions Are Modulated in the Joints in the Chronic Murine Model of Imiquimod-Induced Psoriasis
    Location: Hall F1
    Abstract Poster Presenter: Guillaume LARID, MD,MSc – CHU de Poitiers
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0107: Role of Achilles Elastography in Differentiating Patients with Early Psoriatic Arthritis
    Location: Hall F1
    Abstract Poster Presenter: IRENE MARTIN MARTIN, Sr, MEd – HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0551: Enthesitis Beyond the Surface: Ultrasonographic Unmasking of Preclinical Psoriatic Arthritis in Cutaneous Psoriasis
    Location: Hall F1
    Abstract Poster Presenter: Victor Cazac, n/a – Norwalk Hospital, Nuvance Health
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0101: Enrichment of putative bacteria-reactive gut-derived IL-17+ tissue resident memory helper T cells in arthritic ankles in the SKG mouse model of spondyloarthritis
    Location: Hall F1
    Abstract Poster Presenter: Benjamin Cai, BS – Frazer Institute, The University of Queensland
  • Sunday, Oct 26th
    10:30 AM - 12:30 PM Central Time
    0548: Artificial Intelligence in Axial Spondyloarthritis Diagnosis: Integrating Structural and Inflammatory Lesionsfrom Sacrum MRI
    Location: Hall F1
    Abstract Poster Presenter: Seonyoung Kang, MD – Samsung Medical Center, Sungkyunkwan University School of Medicine
  • Sunday, Oct 26th
    4:15 PM - 5:15 PM Central Time
    26S67: Shifting the Spotlight: New Horizons in the Diagnosis and Management of Psoriatic Arthritis
    Location: W375B
    Moderator: Rebecca Haberman, MD – NYU Langone Health
    Moderator: Mark Hwang, MD,MS – UTHealth Houston
    Session Coordinator: Anca Askanase, MD, MPH – Columbia University Medical Center
    Session Coordinator: Michael Toprover, MD – New York University Langone Health
     CE: 1.00
  • Sunday, Oct 26th
    4:15 PM - 4:45 PM Central Time
    Approach to the Diagnosis and Risk Stratification of Early Onset Psoriatic Arthritis
    Location: W375B
    Speaker: Jose Scher, MD – New York University School of Medicine
  • Sunday, Oct 26th
    4:45 PM - 5:15 PM Central Time
    Bridging the Guidelines: New and Up-and-Coming Therapeutic Options to Managing Psoriatic Arthritis
    Location: W375B
    Speaker: Alexis Ogdie, MD – University of Pennsylvania
  • Monday, Oct 27th
    10:00 AM - 11:30 AM Central Time
    27M18: Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment I: Therapies
    Location: W196A-C
    Abstract Moderator: Alexis Ogdie, MD – University of Pennsylvania
    Abstract Moderator: Soumya Reddy, MD – NYU Grossman School of Medicine
     CE: 0.00
  • Monday, Oct 27th
    10:00 AM - 10:15 AM Central Time
    0873: Sex Differences in Proteomic Profiles and the Impact of Deucravacitinib Treatment in Patients with Active Psoriatic Arthritis: A Pooled Phase 3 Analysis
    Location: W196A-C
    Presenting Author: Lihi Eder, MD, PhD – University of Toronto
  • Monday, Oct 27th
    10:15 AM - 10:30 AM Central Time
    0874: Impact of Deucravacitinib on Disease Activity in Patients With Psoriatic Arthritis (PsA): Results From the Pivotal Phase 3 PsA Studies
    Location: W196A-C
    Presenting Author: Atul Deodhar, MD – Oregon Health & Science University
  • Monday, Oct 27th
    10:30 AM - 10:45 AM Central Time
    0875: Efficacy and Safety of Icotrokinra, a Novel Targeted Oral Peptide (IL-23R-Inhibitor), in Adolescents With Moderate-to-Severe Plaque Psoriasis: Subgroup Analyses From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study (ICONIC-LEAD)
    Location: W196A-C
    Presenting Author: Joseph Merola, MD, MSc, FACR, FAAD – UT Southwestern Medical Center
  • Monday, Oct 27th
    10:45 AM - 11:00 AM Central Time
    0876: Effect of QX002N on Clinical and Radiographic Outcomes in Ankylosing Spondylitis: Results from a Phase III Randomized, Double-blind, Placebo-Controlled Study
    Location: W196A-C
    Presenting Author: Xiaofeng Zeng, MD – Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID)
  • Monday, Oct 27th
    11:00 AM - 11:15 AM Central Time
    0877: Therapeutic Approach in Patients with Arthralgia at Risk of Progression to Psoriatic Arthritis.
    Location: W196A-C
    Presenting Author: Rodrigo Garcia Salinas, MD – Hospital Italiano La Plata
  • Monday, Oct 27th
    11:15 AM - 11:30 AM Central Time
    0878: Effects of IL-17A Inhibition on Entheseal Osteoblast and Fibroblast Dynamics in Psoriatic Arthritis: Insights from the EBIO Biopsy Study
    Location: W196A-C
    Presenting Author: Andreas Ramming, MD, PhD – University Hospital Erlangen
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster II
    Location: Hall F1
     CE: 0.00
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II
    Location: Hall F1
     CE: 0.00
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1405: A Combined Score of Syndesmophytes and Facet Joint Ankylosis Improves Sensitivity to Spinal Structural Damage Progression in Axial Spondyloarthritis
    Location: Hall F1
    Abstract Poster Presenter: Ana Bento da Silva, MD – Leiden University Medical Center
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1406: A Combined Score of Facet Joint Ankylosis and Syndesmophyte Development Correlates Well with Spinal Mobility in Axial Spondyloarthritis
    Location: Hall F1
    Abstract Poster Presenter: Ana Bento da Silva, MD – Leiden University Medical Center
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1407: Trends in Diagnostic Timing and Clinical Features of Axial Spondyloarthritis by Sex and Clinical Subtype: A Multicenter Cohort Over Seven Decades
    Location: Hall F1
    Abstract Poster Presenter: Carla Saad, MD, PhD – Faculdade de Medicina da Universidade de Sao Paulo
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1408: When Damage and Disability Diverge: Unraveling Sex-Based Drivers of Axial Spondyloarthritis Burden
    Location: Hall F1
    Abstract Poster Presenter: Carla Saad, MD, PhD – Faculdade de Medicina da Universidade de Sao Paulo
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1409: The impact of depression in axial spondyloarthritis: Epidemiological insights from the Ankylosing Spondylitis Registry of Ireland (ASRI)
    Location: Hall F1
    Abstract Poster Presenter: Conall Mac Gearailt, MRCP, MBBCH, BAO – Galway University Hospital
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1410: Examining the Interchangeability of Two Different Patient-Reported Global Assessment Measures in an Observational Axial Spondyloarthritis Cohort
    Location: Hall F1
    Abstract Poster Presenter: Connor Vershel, MD – University of Texas at Houston
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1411: Defining Minimal Disease Activity (MDA) in Psoriatic Arthritis (PsA) with the inclusion of Psoriatic Arthritis Impact of Disease (PsAID) scores rather than Health Assessment Questionnaire (HAQ)
    Location: Hall F1
    Abstract Poster Presenter: Conor Coyle, MBBS, BSc – Oxford University Hospitals NHS Trust
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1412: Classification of sacroiliits using an artificial intelligence model
    Location: Hall F1
    Abstract Poster Presenter: Esther Fernandez Guill, MD – Hospital Comarcal del Noroeste
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1413: Restless Legs Syndrome in Patients with Psoriatic Arthritis: Association with Inflammatory, Clinical Parameters, and Comorbidities
    Location: Hall F1
    Abstract Poster Presenter: Esther Toledano, MD, PhD – Hospital Universitario Clínico San Carlos
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1414: Multidimensional Assessment to Differentiate Early Psoriatic Arthritis from Cutaneous Psoriasis
    Location: Hall F1
    Abstract Poster Presenter: Eugeniu Russu, MD, PhD – State Medical and Pharmaceutical University ”Nicolae Testemitanu”; "Timofei Mosneaga" Republican Clinical Hospital
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1415: The Association of Handedness with Radiographic Damage in Patients with Psoriatic Arthritis
    Location: Hall F1
    Abstract Poster Presenter: Fadi Kharouf, MD – Hadassah Medical Center - Toronto Western Hospital
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1417: Common Causes of Hospitalization in Spondyloarthritis Patients: A Nationwide Analysis
    Location: Hall F1
    Abstract Poster Presenter: Faria Sami, MD – The University of Alabama at Birmingham
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1418: Impact of Type 2 Diabetes Mellitus on Cardiovascular Outcomes in Patients with Ankylosing Spondylitis on NSAID Therapy
    Location: Hall F1
    Abstract Poster Presenter: Gurjot Singh, MD – Trihealth Good Samaritan Hospital
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1419: Effectivenss of an educational program on non-radiographic axial spondyloarthritis
    Location: Hall F1
    Abstract Poster Presenter: Hideto Kameda – Toho University
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1420: A Nationwide Analysis of In-Hospital Mortality in Adult Ankylosing Spondylitis
    Location: Hall F1
    Abstract Poster Presenter: Isadora Small, n/a – The Latin School of Chicago
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1421: Impact of Psoriatic Arthritis Disease Activity and Fatigue on Subjective Cognitive Decline (“Brainfog”)
    Location: Hall F1
    Abstract Poster Presenter: Lily Mikolajczak, BS – Georgetown University School of Medicine
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1422: Assessment of Difficulties, Modifications and Use of Work Adaptations in Patients with Axial Spondyloarthritis: Validation of the Dificultax and Modal Questionnaires
    Location: Hall F1
    Abstract Poster Presenter: Mariana Benegas, n/a – sanatorio Mendez
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1423: Genetic and Cytokine Correlates in Ankylosing Spondylitis: rs27038 polymorphism of ERAP1 gene and IL-17 Interactions : A Case-Control Study
    Location: Hall F1
    Abstract Poster Presenter: Meghna Gavali, MBBS, MD (she/her/hers) – Nizam's institute of medical sciences ,Hyderabad
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1424: Mapping Central Nervous System Responses To Painful Stimuli In Patients With Axial Spondyloarthritis
    Location: Hall F1
    Abstract Poster Presenter: Mohamad Bittar, MD, MS – Oregon Health and Science University
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1425: Quantifying Functional Impact of Structural Damage in Psoriatic Arthritis: Insights from a Long-Term Prospective Cohort
    Location: Hall F1
    Abstract Poster Presenter: Pankti Mehta, MD, MBBS, DM – University of Toronto
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1426: Understanding the Drivers of BASDAI and Back Pain Scores in Psoriatic Arthritis
    Location: Hall F1
    Abstract Poster Presenter: Pankti Mehta, MD, MBBS, DM – University of Toronto
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1427: Impact of Biologic Therapy on Subclinical Atherosclerosis and Ventricular Function in Psoriatic Arthritis
    Location: Hall F1
    Abstract Poster Presenter: Rebeca Polina-Lugo, MD (she/her/hers) – Division of Rheumatology, Hospital Universitario, UANL
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1428: Ankylosing Spondylitis Related Mortality Trends in USA from 1999-2020: Analysis of CDC Wonder Database
    Location: Hall F1
    Abstract Poster Presenter: Sanjana Thimmannagari, MBBS – ROCHESTER GENERAL HOSPITAL
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1429: Survival Outcomes in Elderly Patients with Axial Spondyloarthritis and Concomitant Cancer
    Location: Hall F1
    Abstract Poster Presenter: Savannah Bowman, MD – UTHealth Houston
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1430: Redefining BASDAI cut-offs: implications for patients’ eligibility for initiating biologic disease-modifying antirheumatic treatment in axial spondyloarthritis
    Location: Hall F1
    Abstract Poster Presenter: Stylianos Georgiadis, PhD – Rigshospitalet
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1431: Radiographic Sacroiliitis in Psoriatic Arthritis: Clinical, Laboratory, and Spinal Radiographic Correlates in an Indian Cohort
    Location: Hall F1
    Abstract Poster Presenter: Subin Philip, DM – Jawaharlal Institute of Postgraduate Medical Education and Research
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1432: Long-term Radiographic Progression in Early versus Established Axial Spondyloarthritis: A 12-Year Observational Study
    Location: Hall F1
    Abstract Poster Presenter: Tae-jong Kim, MD, PhD – Department of Rheumatology, Chonnam National University Medical School and Hospital
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1433: Identifying Predictors of Difficult-to-Manage Axial Spondyloarthritis: Real-World Insights from a Taiwanese Registry Cohort
    Location: Hall F1
    Abstract Poster Presenter: Yen-An Chang, MD (she/her/hers) – Taipei Veteran General Hospital
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1434: Safety of Prescription NSAIDs in Adults with IBD: Data from a Large Administrative Claims Cohort
    Location: Hall F1
    Abstract Poster Presenter: Adam Mayer, MD – Hackensack University Medical Center
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1435: Impact of Treatment With Upadacitinib on Non-Nociceptive Pain and Its Relevance for the Presence of Residual Symptoms in Axial Spondyloarthritis: Results from a Multicountry Observational Study
    Location: Hall F1
    Abstract Poster Presenter: Denis Poddubnyy, MD, PhD, MSc – University of Toronto
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1436: Angiogenesis Markers in Difficult to Treat Psoriatic Arthritis Patients
    Location: Hall F1
    Abstract Poster Presenter: Devy Zisman, MD – Carmel Medical Center
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1437: Characterization of ORKA-002, a Novel Extended Half-life Monoclonal Antibody Targeting IL-17A/F for the Treatment of Psoriasis and Other Indications
    Location: Hall F1
    Abstract Poster Presenter: Eugenia Levi, PharmD – Oruka Therapeutics
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1438: Similar Efficacy of Bimekizumab in Two Clinical Endotypes of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies and Their Open-Label Extension
    Location: Hall F1
    Abstract Poster Presenter: Félicie Costantino, MD, PhD – AP-HP
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1439: Bimekizumab in Psoriatic Arthritis. A real-world prospective study. Comparison of its efficacy in bDMARD-naive and IL-17A-experienced patients
    Location: Hall F1
    Abstract Poster Presenter: George Fragoulis, MD, PhD (he/him/his) – "Laiko" Hospital - First Department of Propaedeutic and Internal Medicine
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1440: Comparison of standard and tapered dose of biologic treatments in patients with axial spondyloarthritis
    Location: Hall F1
    Abstract Poster Presenter: gEZMIS KIMYON, ASS.PROF MD – MUSTAFA KEMAL UNIVERSITY
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1441: Efficacy and Safety of Vunakizumab in Patients with Active Ankylosing Spondylitis by Cigarette Smoking Status: A Post Hoc Analysis of a Randomized, Double-blind, Phase 2/3 Study
    Location: Hall F1
    Abstract Poster Presenter: Hongbin Li, MD – Affiliated Hospital of Inner Mongolia Medical University
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1442: Modulation of Soluble Biomarkers of Cartilage and Bone Turnover and Inflammation by Zasocitinib (TAK-279), an Oral, Allosteric, Highly Selective and Potent TYK2 Inhibitor, is Associated with Clinical Response in Patients with Active Psoriatic Arthritis
    Location: Hall F1
    Abstract Poster Presenter: Iain McInnes, PhD, FRCP – University of Glasgow
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1443: Long-Term Safety and Efficacy of Upadacitinib in Patients With Psoriatic Arthritis: 5-Year Results From the Phase 3 SELECT-PsA 1 Study
    Location: Hall F1
    Abstract Poster Presenter: Iain McInnes, PhD, FRCP – University of Glasgow
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1444: Real-world comparative effectiveness of tofacitinib, tumor necrosis factor inhibitors, and interleukin-17 inhibitors among patients with axial spondyloarthritis
    Location: Hall F1
    Abstract Poster Presenter: Jeffrey Curtis, MD, MS, MPH – University of Alabama at Birmingham
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1445: Patient Characteristics, and Physician-Reported Treatment Effectiveness and Treatment Satisfaction with Bimekizumab for Axial Spondyloarthritis in the United States: Interim Analysis from a Real-World Study
    Location: Hall F1
    Abstract Poster Presenter: Jessica Walsh, MD, MBA – Salt Lake City Veterans Affairs Health and University of Utah Health
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1446: Persistence of Second-line Treatment in Anti-TNF-experienced Axial Spondyloarthritis Patients: Comparing Cycling Anti–TNF vs Switching to a Different Mechanism of Action
    Location: Hall F1
    Abstract Poster Presenter: José Miguel Senabre, MD, PhD – Hospital Marina Baixa
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1447: Long-term impact of secukinumab on the prevention of psoriatic arthritis in patients with psoriasis: a 5-year pooled analysis of the ERASURE, FIXTURE and SCULPTURE studies
    Location: Hall F1
    Abstract Poster Presenter: Laura Coates, MD, PhD – University of Oxford
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1448: Influence of Sex on the Therapeutic Persistence of Guselkumab in Psoriatic Disease: a Retrospective National Cohort Study
    Location: Hall F1
    Abstract Poster Presenter: Laure Gossec, MD;PhD – Sorbonne Universite and Pitie-Salpetriere Hospital
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1449: Bimekizumab Demonstrated Comparable One-Year Efficacy in Male and Female Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
    Location: Hall F1
    Abstract Poster Presenter: Lianne S. Gensler, MD – University of California San Francisco
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1450: The Novel Digital Therapeutic Axia Improves Disease Activity, Functionality, and Quality of Life in Axial Spondyloarthritis Patients: Results from a Randomized Controlled Trial (Bechterew-App Trial)
    Location: Hall F1
    Abstract Poster Presenter: Marc Schmalzing, MD – University Hospital Wuerzburg
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1451: Bimekizumab was Efficacious Regardless of Age, BMI, CRP, or HLA-B27 Status: 1-Year Results from Two Phase 3 Studies
    Location: Hall F1
    Abstract Poster Presenter: Marina Magrey, MD – Case Western Reserve University School of Medicine/University Hospitals Cleveland
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1452: Clinical and Demographic Characteristics of Treatment-Refractory Axial Spondyloarthritis: Data from the Greek AxSpA Registry
    Location: Hall F1
    Abstract Poster Presenter: Nikolaos Kougkas, MD;PhD (he/him/his) – 4th Department of Internal Medicine, Aristotle University
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1453: Real-World Comparative Effectiveness of Upadacitinib in Psoriatic Arthritis: Evaluation of Switching to Upadacitinib Versus Tumor Necrosis Factor Inhibitors or Interleukin-17 Inhibitors After First-Line Tumor Necrosis Factor Inhibitors
    Location: Hall F1
    Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1454: Long-Term Safety and Tolerability of Bimekizumab Treatment Across Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update from the Phase 3 Studies
    Location: Hall F1
    Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1455: Sonelokimab in Patients With Active Psoriatic Arthritis Who Are Naive to Biologic DMARDs: Phase 2 ARGO Analysis and Phase 3 IZAR-1 Study Design
    Location: Hall F1
    Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1456: Long-Term Safety of Tildrakizumab Through Week 208 in Patients With Psoriatic Arthritis: Results From the Phase 2b Open-Label Extension Study
    Location: Hall F1
    Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1457: Real-world Patient Trajectories in Psoriasis and Psoriatic Arthritis: a Retrospective Study
    Location: Hall F1
    Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1458: Clinical Efficacy of Bimekizumab Treatment up to 2 Years Across Patients with Psoriatic Arthritis and Varying Baseline Joint Involvement: Results from a Post Hoc Analysis of Two Pooled Phase 3 Studies
    Location: Hall F1
    Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1459: Fungal Infections, Including Candida, in Patients With Active Psoriatic Arthritis (PsA) Treated With Secukinumab: A Pooled Analysis of 9 Phase 3 Trials
    Location: Hall F1
    Abstract Poster Presenter: Shikha Singla, MD – MCW
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1460: Effect of Guselkumab and IL-17 Inhibitors on Work Productivity and Activity Impairment in Psoriatic Arthritis: 6-Month Results of the PsABIOnd Observational Study
    Location: Hall F1
    Abstract Poster Presenter: Stefan Siebert, MD – University of Glasgow
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1461: Digital Behavioral Therapy Improves Outcome in Patients With Axial Spondyloarthritis And Persistent Pain: Results From a Randomized Controlled Trial
    Location: Hall F1
    Abstract Poster Presenter: Uta Kiltz, MD – Rheumazentrum Ruhrgebiet
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1462: Five-Year Results of Secukinumab on Minimal Disease Activity (MDA) Components and the Impact of Biologic Treatment Status on Effectiveness and Safety in Patients With Psoriatic Arthritis: Real-World Data From the SERENA Study
    Location: Hall F1
    Abstract Poster Presenter: Uta Kiltz, MD – Rheumazentrum Ruhrgebiet
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1463: Effective Prevention of Psoriatic Arthritis with Secukinumab: A 5-Year Observation from the SERENA Study
    Location: Hall F1
    Abstract Poster Presenter: Uta Kiltz, MD – Rheumazentrum Ruhrgebiet
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1464: Incidence of Major Adverse Cardiovascular Events (MACE) in Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis Patients With and Without Cardiovascular Risk Factors Treated With Secukinumab: Five-Year Safety Data from the Real-World SERENA Study
    Location: Hall F1
    Abstract Poster Presenter: Uta Kiltz, MD – Rheumazentrum Ruhrgebiet
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1465: Sustainability of Clinical Response Through 2 Years Among Upadacitinib-Treated Patients With Axial Spondyloarthritis: Data From the SELECT-AXIS 1 and SELECT-AXIS 2 Trials
    Location: Hall F1
    Abstract Poster Presenter: Victoria Navarro-Compán, MD – La Paz University Hospital
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1466: Impact of Bimekizumab on Spinal MRI Inflammation and Structural Lesions in Patients with Radiographic Axial Spondyloarthritis: 2-Year CANDEN Scoring Results from a Phase 3 Study and Its Open-Label Extension
    Location: Hall F1
    Abstract Poster Presenter: Walter P P. Maksymowych, MD, FRCPC, MRCP, FACP – University of Alberta
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1416: Structural Damage Progression in the Spine in Patients with Psoriatic Arthritis: Findings from a Longitudinal Cohort Study
    Location: Hall F1
    Abstract Poster Presenter: Fadi Kharouf, MD – Hadassah Medical Center - Toronto Western Hospital
  • Monday, Oct 27th
    1:00 PM - 2:30 PM Central Time
    27M47: Axial Spondyloarthritis and Its Mimics Across the Age Spectrum: Emerging Concepts
    Location: W375B
    Moderator: Joerg Ermann, MD – Brigham and Women's Hospital
    Moderator: Rouhin Sen, MD,MS – University of Alabama at Birmingham
    Session Coordinator: Grant Louie, MD, MHS – Arthritis and Rheumatism Associates, PC
    Session Coordinator: Lesley Jackson, MD, MSPH – University of Alabama at Birmingham
     CE: 1.50
  • Monday, Oct 27th
    1:00 PM - 1:30 PM Central Time
    Diagnosis and Management of Axial Spondyloarthritis in Juvenile Patients
    Location: W375B
    Speaker: Pamela Weiss, MD – Childrens Hospital of Philadelphia
  • Monday, Oct 27th
    1:30 PM - 2:00 PM Central Time
    Diagnosis and Long-Term Treatment Outcomes of Axial Spondyloarthritis in Adults
    Location: W375B
    Speaker: Walter P P. Maksymowych, MD, FRCPC, MRCP, FACP – University of Alberta
  • Monday, Oct 27th
    2:00 PM - 2:30 PM Central Time
    If Not Axial Spondyloarthritis, Then What?
    Location: W375B
    Speaker: Lianne S. Gensler, MD – University of California San Francisco
  • Monday, Oct 27th
    3:00 PM - 4:30 PM Central Time
    27M62: Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes I: Advances in Psoriatic Disease
    Location: S103
    Abstract Moderator: Dafna Gladman, MD, FRCPC, FACR, MACR – University of Toronto, Toronto Western Hospital
    Abstract Moderator: Sibel Aydin, MD – University of Ottawa - Ottawa
     CE: 0.00
  • Monday, Oct 27th
    3:00 PM - 3:15 PM Central Time
    1710: Defining sonographic enthesitis in psoriatic arthritis: Developing a data- and expert-driven definition for inflammatory enthesitis at the single enthesis level
    Location: S103
    Presenting Author: Andre Lucas Ribeiro (he/him/his) – Universidade Federal do Rio Grande do Sul
  • Monday, Oct 27th
    3:15 PM - 3:30 PM Central Time
    1711: Dysfunctional Neurobiology Of The Insula Characterizes Fatigue In Psoriatic Arthritis
    Location: S103
    Presenting Author: Andrew McGucken, MD – University of Glasgow
  • Monday, Oct 27th
    3:30 PM - 3:45 PM Central Time
    1712: Reduced Cardiometabolic Burden and Inflammation in Patients with Psoriatic Arthritis Cared for in a Multi-Disciplinary, Combined Psoriasis-Psoriatic Arthritis Center
    Location: S103
    Presenting Author: Rebecca Haberman, MD – NYU Langone Health
  • Monday, Oct 27th
    3:45 PM - 4:00 PM Central Time
    1713: Diagnostic Delay in Psoriatic Arthritis and its Impact on Radiological Outcomes: A Systematic Review and Meta-analysis of 23,894 Patients
    Location: S103
    Presenting Author: Mohamed Abdelsalam, MSc, MBBCH – MUST University
  • Monday, Oct 27th
    4:00 PM - 4:15 PM Central Time
    1714: The perimenopause period is associated with increased levels of disease activity in psoriatic arthritis
    Location: S103
    Presenting Author: Lihi Eder, MD, PhD – University of Toronto
  • Monday, Oct 27th
    4:15 PM - 4:30 PM Central Time
    1715: Spondyloarthritis and Psoriatic Arthritis Patients Under Immunosuppressive Conventional and Biologic DMARDs: Favorable Disease Safety and Attenuated Immunogenicity Following Recombinant Herpes Zoster Vaccination
    Location: S103
    Presenting Author: Carla Saad, MD, PhD – Faculdade de Medicina da Universidade de Sao Paulo
  • Tuesday, Oct 28th
    10:00 AM - 11:30 AM Central Time
    28T15: Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Basic Science
    Location: W190A-B
    Abstract Moderator: Monica Guma, MD, PhD – UCSD
    Abstract Moderator: Iannis Adamopoulos, PhD – Harvard Medical School, BIDMC, Division of Rheumatology
     CE: 0.00
  • Tuesday, Oct 28th
    10:00 AM - 10:15 AM Central Time
    1752: Prg4+ Ligament Cells Are Involved in Ligament Ossification in Ankylosing Spondylitis
    Location: W190A-B
    Presenting Author: KUNHAI TANG, BS – fudan University
  • Tuesday, Oct 28th
    10:15 AM - 10:30 AM Central Time
    1753: Axial Psoriatic Arthritis is Phenocopied in a Humanized Mouse Model
    Location: W190A-B
    Presenting Author: Maria de la Luz Garcia-Hernandez, PhD – University of Rochester
  • Tuesday, Oct 28th
    10:30 AM - 10:45 AM Central Time
    1754: B3GNT2 Regulates Integrin β3 Glycosylation and Th17/Treg Imbalance in Axial Spondyloarthritis Pathogenesis
    Location: W190A-B
    Presenting Author: Jing Liu, PhD – Fudan University
  • Tuesday, Oct 28th
    10:45 AM - 11:00 AM Central Time
    1755: Multi-Omic Profiling Of CD8+ T Cells In Axial Spondyloarthritis (axSpA) And Reactive Arthritis (ReA) Implicates Common Pathways
    Location: W190A-B
    Presenting Author: Zoya Qaiyum, MSc – Schroeder Arthritis Institute, University Health Network
  • Tuesday, Oct 28th
    11:00 AM - 11:15 AM Central Time
    1756: Exosomal Cargo and Surface Markers: Informative Signals in Axial Spondyloarthritis
    Location: W190A-B
    Presenting Author: Robert Inman, MD – University Health Network
  • Tuesday, Oct 28th
    11:15 AM - 11:30 AM Central Time
    1757: Skin-to-Joint Immune Cell Migration and Synovial Reprogramming in Psoriatic Arthritis Onset
    Location: W190A-B
    Presenting Author: Maria Gabriella Raimondo, MD (she/her/hers) – Uniklinikum Erlangen, Department of Medicine 3, Rheumatology and Immunology
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes Poster III
    Location: Hall F1
     CE: 0.00
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster III
    Location: Hall F1
     CE: 0.00
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2305: Predictors of Hospitalization and Emergency Department Visits Among Patients with Psoriatic Disease: Insights from the Forward Psoriasis Registry
    Location: Hall F1
    Abstract Poster Presenter: Alexis Ogdie, MD – University of Pennsylvania
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2306: Prevalence and Clinical Significance of the Gastrointestinal Fat Halo Sign in Patients with Psoriatic Arthritis: A Cross-Sectional Study
    Location: Hall F1
    Abstract Poster Presenter: Amir Haddad, MD – Carmel Medical Centre
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2309: Lifestyle behaviours and disease activity in patients with psoriatic arthritis: the Dutch south west psoriatic arthritis study
    Location: Hall F1
    Abstract Poster Presenter: Batoul Hojeij, n/a (she/her/hers) – Erasmus MC
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2310: Neuropeptide influence in nociception and inflammation through immune system modulation in SPA patients
    Location: Hall F1
    Abstract Poster Presenter: ELENA GRAU GARCIA, PhD – HUP La Fe
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2311: Obstructive Sleep Apnea Syndrome in Patients with Psoriatic Arthritis and Its Relationship with Disease Activity and Comorbidities
    Location: Hall F1
    Abstract Poster Presenter: Esther Toledano, MD, PhD – Hospital Universitario Clínico San Carlos
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2313: From Plaque to Plaque: Bridging Oral and Systemic Inflammation in Psoriasis and PsA
    Location: Hall F1
    Abstract Poster Presenter: Guru Vijay Chagalakondu, DM – Employee State Insurance Corporation (ESIC)
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2314: Radiographic and Ultrasonographic Assessments of Sesamoid Index in Patients with Psoriatic Arthritis
    Location: Hall F1
    Abstract Poster Presenter: Hung Vo, MD;RhMSUS (he/him/his) – Boston Medical Center
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2316: Sexual Dysfunction in Women with Axial Spondyloarthritis: A Meta-Analysis of FSFI Total and Domain Scores
    Location: Hall F1
    Abstract Poster Presenter: Jose Fernando Verztman, MD – Hospital Federal dos Servidores do Estado do Rio de Janeiro
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2317: Cardiovascular Risk and Psoriatic Arthritis Features: Dactylitis may Predict Cardiovascular Events
    Location: Hall F1
    Abstract Poster Presenter: Katherine K. Benson, MD, BA – University of California, San Diego
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2318: Practice Patterns and Barriers in the Referral, Management and Monitoring of Axial Spondyloarthritis: Insights from an Online Survey of Rheumatologists
    Location: Hall F1
    Abstract Poster Presenter: Khalid Al Naqbi, MD, MSc, CCD, FRCPC, FACP, FACR (he/him/his) – Sheikh Tahnoon Medical City
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2319: Reducing selection bias while maintaining precision through an integrated analysis: 2-year longitudinal analysis of imaging outcomes in the SPondyloArthritis Caught Early cohort
    Location: Hall F1
    Abstract Poster Presenter: Liese de Bruin, MSc – Leiden University Medical Center
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2320: Sleep Disturbance in Psoriatic Arthritis: Prevalence by Minimal Disease Activity Status and Associated Clinical Factors
    Location: Hall F1
    Abstract Poster Presenter: Lourdes Perez Chada, MD,MMSc – Harvard Medical School
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2321: Uncovering Clinical Phenotypes of Sexual Dysfunction in Spondyloarthritis: A Multidimensional Analysis
    Location: Hall F1
    Abstract Poster Presenter: Martín Valdez-López, MD – Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubiran
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2322: Gender-related Differences in Peripheral and Axial Spondyloarthritis
    Location: Hall F1
    Abstract Poster Presenter: Tuncay Duruoz, MD, -None- – Marmara University
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2323: Short-term predictive factors for the development of psoriatic arthritis in patients with psoriasis: findings from a joint consultation between Rheumatology and Dermatology
    Location: Hall F1
    Abstract Poster Presenter: Mitndbaim Parra Moreno, MD – Reina Sofia University Hospital, Cordoba
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2324: Early Prediction of Complex Forms of Spondyloarthritis Using Artificial Intelligence: A Modeling Study Based on Routine Clinical Data
    Location: Hall F1
    Abstract Poster Presenter: MOHAMMED KHALIL JNYAH, MD (he/him/his) – University Hospital Center Hassan II of Fez, Faculty of Medicine, Dentistry and pharmacy Sidi Mohamed Ben Abdellah of Fez, Morocco
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2325: Association of galectin-3 and Myocardial Dysfunction in Patients with Psoriatic Arthritis
    Location: Hall F1
    Abstract Poster Presenter: Natalia Guajardo-Jauregui, MD – Hospital Universitario "Dr. Jose E. Gonzalez", Monterrey, Mexico
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2326: Impact of Regular Exercise, Mobility Impairment, and Obesity on Quality of Life in Patients with Axial Spondyloarthritis: A Cross-Sectional Analysis from the Brazilian Registry of Spondyloarthritis
    Location: Hall F1
    Abstract Poster Presenter: Rafael Bassara Macedo, MD – Rheumatology Division - University of São Paulo
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2327: Persistent Pain in PsA: A Distinct Phenotype of Depression, Fatigue, And Catastrophizing
    Location: Hall F1
    Abstract Poster Presenter: Rebecca Haberman, MD – NYU Langone Health
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2328: Increased Risk of Stroke In Patients With Psoriasis: A Systematic Review And Meta-Analysis
    Location: Hall F1
    Abstract Poster Presenter: Rubab Rizwan, MD – VBMC,Nuvance Health
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2329: Increased Risk of Atrial Fibrillation In Patients With Psoriasis: A Systematic Review And Meta-Analysis
    Location: Hall F1
    Abstract Poster Presenter: Sehneet Grewal, MBBS (she/her/hers) – Nuvance Health
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2330: Correlation of Comorbidities with Psoriatic Arthritis Duration in Elderly Veterans - A Retrospective Cohort Study
    Location: Hall F1
    Abstract Poster Presenter: Siba Raychaudhuri, MD – UC Davis, School of Medicine/ VA Medical Center, Sacramento
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2331: Coping with Rheumatic Stressors in Axial Spondyloarthritis: Association with Patient Characteristics and Disease Phenotypes and Changes Over Time
    Location: Hall F1
    Abstract Poster Presenter: Sofia Ramiro, MD, PhD – Leiden University Medical Center
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2333: Validation of a Corrected Axial Spondyoarthritis Metrology Index in 9 Randomized Clinical Trials
    Location: Hall F1
    Abstract Poster Presenter: Sofia Ramiro, MD, PhD – Leiden University Medical Center
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2334: Development and validation analysis of a Corrected Axial Spondyloarthritis Metrology Index
    Location: Hall F1
    Abstract Poster Presenter: Sofia Ramiro, MD, PhD – Leiden University Medical Center
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2336: Early Axial Spondyloarthritis in Latin America: Prevalence and Regional Differences from the "ESPALDA" Multinational Registry
    Location: Hall F1
    Abstract Poster Presenter: Wilson Bautista-Molano, Sr, MD, PhD – University Hospital Fundación Santa Fe de Bogotá
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2337: A Mediation Analysis of Tofacitinib's Effects on SF-36: The Roles of Fatigue, Pain, Stiffness, and Mobility in Ankylosing Spondylitis
    Location: Hall F1
    Abstract Poster Presenter: Xenofon Baraliakos, MD – Rheumazentrum Ruhrgebiet
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2338: Real-World Outcomes of Combined Tofacitinib and TNF Inhibitor Therapy in Refractory Inflammatory Arthritis: A Tertiary Care Experience from India
    Location: Hall F1
    Abstract Poster Presenter: Aashish Agrawal, MD, MBBS – Hinduja Hospital
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2339: Joint Groups Involved in Early Oligoarticular Psoriatic Arthritis and the Impact of Apremilast Treatment: Data From FOREMOST
    Location: Hall F1
    Abstract Poster Presenter: Alen Zabotti, MD, MSc – Azienda Sanitaria Universitaria del Friuli Centrale
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2340: Lighten the Load: Artificial Intelligence Reveals Body Mass Index Outranks Treatment in One-Year Psoriatic Arthritis Outcomes—Findings from the SPEED Trial
    Location: Hall F1
    Abstract Poster Presenter: Alexander Garaiman, n/a – Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2341: Bimekizumab Treatment Resulted in Long-Term Sustained Reductions in Disease Impact Assessed by the Psoriatic Arthritis Impact of Disease (PsAID)-12 Questionnaire in Patients with Active Psoriatic Arthritis: Up to 3-Year Results from Two Phase 3 Studies
    Location: Hall F1
    Abstract Poster Presenter: Ana-Maria Orbai, MD, MHS – Johns Hopkins University School of Medicine, Division of Rheumatology
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2342: Real-World Effectiveness and Satisfaction in Biologic-Naïve Patients With Psoriatic Arthritis and Limited Joint Involvement Treated With Risankizumab in the United States and Europe
    Location: Hall F1
    Abstract Poster Presenter: Andrew Ostor, MD – Australian National University
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2343: Risk of Arrhythmias Following IL-17 Inhibitor Use; A Pharmacosurvellience Study of FDA Adverse Event Reporting System (FAERS)
    Location: Hall F1
    Abstract Poster Presenter: Asim Khanfar, MD – Rochester General Hospital
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2344: Impact of Bimekizumab Use in Spondyloarthritis and Psoriatic Arthritis: Persistence Study in Routine Clinical Practice in Spain (BIMPACT study)
    Location: Hall F1
    Abstract Poster Presenter: Cristina Valero, MD – Hospital de la Princesa
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2345: Biological Sex-Related Differences in Radiographic Progression and Relationship with Early Clinical Response: Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo‑Controlled Study in Biologic-Naive Participants with Active Psoriatic Arthritis Treated with Guselkumab
    Location: Hall F1
    Abstract Poster Presenter: Dafna Gladman, MD, FRCPC, FACR, MACR – University of Toronto, Toronto Western Hospital
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2346: Back in Action: Six Months of Biological Therapy Improve Sexual Function in Men with Ankylosing Spondylitis
    Location: Hall F1
    Abstract Poster Presenter: Daniel Zavada, MD – Charles University, Third Faculty of Medicine
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2347: Bimekizumab Treatment Resulted in Patients with Axial Spondyloarthritis Maintaining Their Clinical Responses Over 3 Years: Results from Two Phase 3 Studies and Their Open-Label Extension
    Location: Hall F1
    Abstract Poster Presenter: Fabian Proft, MD – Charité Universityhospital Berlin
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2348: Efficacy and safety of dual biological therapy in the treatment of rheumatic diseases: experience from a single highly specialized center.
    Location: Hall F1
    Abstract Poster Presenter: Francesco Fulvio Bizzarri, MD – Complejo Hospitalario de Jaen
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2349: Classification of "Difficult-to-Manage Axial Spondyloarthritis": A Real-World Cohort Study Evaluating the ASAS 2024 Criteria Over Time
    Location: Hall F1
    Abstract Poster Presenter: Gözde Kart Bayram, MD – Hacettepe University
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2350: Multicenter study on the use of Upadacitinib: sex specific results in Spondyloarthritis
    Location: Hall F1
    Abstract Poster Presenter: Guillermo Gonzalez Mozo de Rosales, MD – Basurto University Hospital
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2351: Modulation of Tyrosine Kinase 2- and Disease-Related Biomarkers by Zasocitinib (TAK-279), an Oral, Allosteric, Highly Selective and Potent Tyrosine Kinase 2 Inhibitor, Is Associated With Clinical Response in Patients with Active Psoriatic Arthritis
    Location: Hall F1
    Abstract Poster Presenter: Iain McInnes, PhD, FRCP – University of Glasgow
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2352: Long-Term Uveitis Rates with Bimekizumab Treatment Across Pooled Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update
    Location: Hall F1
    Abstract Poster Presenter: Irene van der Horst-Bruinsma, MD, PhD – Radboud umc
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2353: Efficacy of Vunakizumab in Reducing Pain in Ankylosing Spondylitis: A Post-Hoc Analysis of a Phase 2/3 Clinical Trial
    Location: Hall F1
    Abstract Poster Presenter: Xu Jian, PhD – First Affiliated Hospital of Kunming Medical University
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2354: ChatGPT or SPSS? A comparison between AI-based and Traditional Statistical Analysis of Longitudinal Inflammatory Marker Data in Spondyloarthritis
    Location: Hall F1
    Abstract Poster Presenter: José Miguel Sequí-Sabater, Jr, MD,MSc (he/him/his) – La Ribera University Hospital, Rheumatology Department
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2355: Ixekizumab Provided Rapid Improvement in Key Patient Subgroups with Psoriatic Arthritis: Findings from a Prospective Observational Study in the United States of Patients Initiating Ixekizumab or Interleukin-23 Inhibitors
    Location: Hall F1
    Abstract Poster Presenter: KURT OELKE, MD – rheumatic disease center
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2356: Clinical Efficacy in Male and Female Patients With Active Psoriatic Arthritis Treated With Deucravacitinib: A Pooled Analysis of Pivotal Phase 3 Studies
    Location: Hall F1
    Abstract Poster Presenter: Lihi Eder, MD, PhD – University of Toronto
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2357: Impact of Sonelokimab, a Novel IL-17A- and IL-17F-Inhibiting Nanobody, in Active Psoriatic Arthritis: Key Subgroup Analyses in the Randomized, Double-Blind, Placebo-Controlled Phase 2 ARGO Trial
    Location: Hall F1
    Abstract Poster Presenter: Lihi Eder, MD, PhD – University of Toronto
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2358: Bimekizumab Demonstrated Early and Sustained Efficacy Regardless of Baseline Characteristics in Patients with Active Psoriatic Arthritis: Pooled Post Hoc Results up to 1-Year from Two Phase 3 Studies
    Location: Hall F1
    Abstract Poster Presenter: Lihi Eder, MD, PhD – University of Toronto
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2359: Combination Of ­TNF Inhibitors And NSAIDs Versus ­TNF Inhibitors Alone On The Progression Of Structural Damage In The Spine And Hip: a Retrospective Study In 262 Patients With Radiographic Axial Spondyloarthritis
    Location: Hall F1
    Abstract Poster Presenter: MARIA KONSTA, MD, PhD (she/her/hers) – Sismanoglion Hospital, Athens, Greece
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2360: Treatment adherence in ankylosing spondylitis: A comparison of TNFi, IL-17i, and JAKi using real-world data
    Location: Hall F1
    Abstract Poster Presenter: Marina Magrey, MD – Case Western Reserve University School of Medicine/University Hospitals Cleveland
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2361: Secondary Outcomes from a Series of N-of-1 NSAID Trials in Axial Spondyloarthritis: Functional, Quality-of-Life, and Safety Results from a Bayesian Analysis
    Location: Hall F1
    Abstract Poster Presenter: Mark Hwang, MD,MS – UTHealth Houston
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2362: Long-Term Efficacy and Safety of Risankizumab for csDMARD-IR Patients With Active Psoriatic Arthritis: 244-Week Results From the KEEPsAKE 1 Trial
    Location: Hall F1
    Abstract Poster Presenter: Mauro Keiserman, MD – Rheumatology Section, Pontifical Catholic University, School of Medicine
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2363: Impact of Biologic Therapies on Cardiovascular and Venous Thromboembolic Events in Psoriatic Arthritis: Real-World Evidence
    Location: Hall F1
    Abstract Poster Presenter: Milad Heydari-Kamjani, DO – University Hospitals Cleveland Medical Center/ Case Western Reserve University
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2364: Real-World Characteristics and Treatment Patterns of Difficult-to-Treat Psoriatic Arthritis
    Location: Hall F1
    Abstract Poster Presenter: Milad Heydari-Kamjani, DO – University Hospitals Cleveland Medical Center/ Case Western Reserve University
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2365: Sustained Efficacy up to 3 Years with Bimekizumab Treatment Across GRAPPA Core Domains in Patients with Psoriatic Arthritis: Long-Term Results from Two Phase 3 Trials
    Location: Hall F1
    Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2366: Association Between Skin and Joint Symptom Control and Patient-reported Pain and Health Status Among Patients with Psoriatic Arthritis in the Corevitas Psoriatic Arthritis/spondyloarthritis Registry Initiating Biologic or Targeted Synthetic Disease-modifying Antirheumatic Drugs
    Location: Hall F1
    Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2367: Real-World Effectiveness of Risankizumab on Axial Symptoms in Biologic-Naïve Patients With Psoriatic Arthritis in the United States and Europe
    Location: Hall F1
    Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2368: Inhibition of Structural Damage Progression with Guselkumab, a Selective IL-23i, in Participants with Active PsA: Results Through Week 24 of the Phase 3b, Randomized, Double-Blind, Placebo-Controlled APEX Study
    Location: Hall F1
    Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2369: Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve and Biologic-Experienced Patients with Psoriatic Arthritis: Comparison of Guselkumab versus Subcutaneous Interleukin-17A Inhibitors
    Location: Hall F1
    Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2370: Comparative Efficacy and Safety of IL-17 Inhibitors Versus Adalimumab in Biologic-Naive Psoriatic Arthritis Patients: A Meta-Analysis of Randomized Controlled Trials
    Location: Hall F1
    Abstract Poster Presenter: Punith Chirumamilla, MD (he/him/his) – Baptist Memorial Hospital North Mississippi
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2371: A Predictive Model Combining Clinical and Laboratory Parameters to Predict Anti-tnf Response in Patients with Psoriatic Arthritis
    Location: Hall F1
    Abstract Poster Presenter: Raquel Granados, MD – Hospital Universitario Reina Sofia
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2372: Treatment Outcome and Persistence of IL-23 Inhibitors in Real World Cohort of PsA Patients- A Retrospective Study
    Location: Hall F1
    Abstract Poster Presenter: Reut Tzemach, MD (she/her/hers) – Sourasky Medical Center
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2373: Effectiveness and Tolerability of Guselkumab or TNF inhibitors as Second-Line Treatment After Receiving a TNF inhibitor as First-Line Therapy to Treat Active Psoriatic Arthritis: 52-Week Interim Data from the Manhattan Study
    Location: Hall F1
    Abstract Poster Presenter: Rocio Gonzalez Molina, PhD – Hospital Reina Sofía
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2374: Bimekizumab Efficacy And Safety Through 5 Years In Patients With Moderate To Severe Plaque Psoriasis In The US And Canada
    Location: Hall F1
    Abstract Poster Presenter: Saakshi Khattri, MD, MBBS – Mount Sinai Medical Center
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2375: Ixekizumab Provided Rapid Improvements in Quality of Life and Disease Activity in Patients with Psoriatic Arthritis: Findings from a Real-World Study in the United States of Patients Initiating Ixekizumab or Interleukin-23 Inhibitors
    Location: Hall F1
    Abstract Poster Presenter: Shikha Singla, MD – MCW
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2376: Efficacy And Safety of Vunakizumab in Patients with Active Ankylosing Spondylitis Stratified by Disease Course: A Post-hoc Analysis of a Randomized, Double-Blind, Phase 2/3 Trial
    Location: Hall F1
    Abstract Poster Presenter: Xiaofei Shi, MD – The First Affiliated Hospital of Henan University of Science and Technology
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2307: Peripheral Manifestations In Axial And Peripheral Spondyloarthritis: A Systematic Literature Review On Their Assessment In Clinical Trials
    Location: Hall F1
    Abstract Poster Presenter: AUGUSTA ORTOLAN, MD, PhD, MSc – Policlinico Universitario Agostino Gemelli IRCSS
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2335: The 14-3-3 eta AAb biomarker improves discriminative performance of CRP and HLA-B27 to differentiate people with radiographic axSpA from those with mechanical back pain.
    Location: Hall F1
    Abstract Poster Presenter: Walter P P. Maksymowych, MD, FRCPC, MRCP, FACP – University of Alberta
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2308: Physical Function Mediates Most—but Not All—of the Effect of Disease Activity on Health-Related Quality of Life in Axial Spondyloarthritis: A 10-Year Longitudinal Analysis
    Location: Hall F1
    Abstract Poster Presenter: AUGUSTA ORTOLAN, MD, PhD, MSc – Policlinico Universitario Agostino Gemelli IRCSS
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2332: Development and validation of a Disease Activity index for PSoriatic Arthritis based on 44 joints: DAPSA44
    Location: Hall F1
    Abstract Poster Presenter: Sofia Ramiro, MD, PhD – Leiden University Medical Center
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2312: Sociodemographic Characteristics and Healthcare Utilization in Patients with IBD-Associated Arthritis vs. IBD Alone: A Nationwide Inpatient Analysis
    Location: Hall F1
    Abstract Poster Presenter: Faria Sami, MD – The University of Alabama at Birmingham
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2315: Alterations in the Gut Microbiome in Ankylosing Spondylitis and Their Correlation with Disease Activity
    Location: Hall F1
    Abstract Poster Presenter: Hyemin Jeong, MD – Soonchunhyang University Hospital
  • Tuesday, Oct 28th
    1:00 PM - 2:00 PM Central Time
    28T40: Beyond NETs: Alternative Roles of Neutrophils in Spondyloarthritis
    Location: W181A-C
    Moderator: Iannis Adamopoulos, PhD – Harvard Medical School, BIDMC, Division of Rheumatology
    Session Coordinator: Christian Lood, PhD – University of Washington
    Session Coordinator: Sadiq Umar, PhD – University of Illinois at Chicago
     CE: 1.00
  • Tuesday, Oct 28th
    1:00 PM - 1:30 PM Central Time
    Role of Neutrophil Interleukin-23 in Spondyloarthropathy Spectrum Disorders
    Location: W181A-C
    Speaker: Dennis McGonagle, n/a – Leeds Institute of Rheumatic and Musculoskeletal Medicine (LIRMM), University of Leeds
  • Tuesday, Oct 28th
    1:30 PM - 2:00 PM Central Time
    HIF-1α and MIF Enhance Neutrophil-Driven Type 3 Immunity and Chondrogenesis in a Murine Spondyloarthritis Model
    Location: W181A-C
    Speaker: Nigil Haroon, MD, PhD, DM, FRCPC, FRCP, MBA – University Health Network
  • Tuesday, Oct 28th
    3:00 PM - 4:30 PM Central Time
    28T56: Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes II: Advances in Axial Spondyloarthritis
    Location: W183A-C
    Abstract Moderator: Abhijeet Danve, MD, MHS – Yale University
    Abstract Moderator: Ajesh Maharaj, PhD,MBBS,FACR – University
     CE: 0.00
  • Tuesday, Oct 28th
    3:00 PM - 3:15 PM Central Time
    2633: Comparative 3-year Safety Outcomes in Patients with Ankylosing Spondylitis Initiating JAK Inhibitor or TNF Inhibitor Therapy
    Location: W183A-C
    Presenting Author: Hsin-Hua Chen, MD, PhD – Taichung Veterans General Hospital
  • Tuesday, Oct 28th
    3:15 PM - 3:30 PM Central Time
    2634: Sex differences in medication discontinuation in axial spondyloarthritis
    Location: W183A-C
    Presenting Author: Eric Roberts, PhD, MPH – University of California, San Francisco
  • Tuesday, Oct 28th
    3:30 PM - 3:45 PM Central Time
    2635: Differences in structural lesions of the spine between patients with early axSpA and non-axSpA chronic back pain: 2-year results of the SPACE Cohort
    Location: W183A-C
    Presenting Author: Sofia Ramiro, MD, PhD – Leiden University Medical Center
  • Tuesday, Oct 28th
    3:45 PM - 4:00 PM Central Time
    2636: Autoantibodies to 14-3-3 eta: A Novel Diagnostic Biomarker for Axial Spondyloarthritis
    Location: W183A-C
    Presenting Author: Raj Sengupta, MD – Royal National Hospital for Rheumatic Diseases
  • Tuesday, Oct 28th
    4:00 PM - 4:15 PM Central Time
    2637: Initial Phospholipid Transferase Activity Is Predictive of Five-Year Sacroiliac Radiographic Progression in Axial Spondyloarthritis: Findings From the DESIR Cohort
    Location: W183A-C
    Presenting Author: Frank Verhoeven, MD,PhD – CHU Besançon
  • Tuesday, Oct 28th
    4:15 PM - 4:30 PM Central Time
    2638: Asemblenet: A Hybrid AI Model for Mri-based Classification of Ankylosing Spondylitis
    Location: W183A-C
    Presenting Author: Miral Hamed, MD, MRCP, MBBCH – Hamad medical corporation
  • Wednesday, Oct 29th
    11:30 AM - 1:00 PM Central Time
    29W15: Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment II: Pathogenesis, Exercise, and Dietary Interventions
    Location: W181A-C
    Abstract Moderator: Jose Scher, MD – New York University School of Medicine
    Abstract Moderator: Abin Puravath, MD – Cedars-Sinai
     CE: 0.00
  • Wednesday, Oct 29th
    11:30 AM - 11:45 AM Central Time
    2687: Glucagon-like peptide-1 receptor agonists therapy is associated in improvement in psoriatic arthritis-related and metabolic outcomes: A retrospective analysis of two cohorts
    Location: W181A-C
    Presenting Author: Lihi Eder, MD, PhD – University of Toronto
  • Wednesday, Oct 29th
    11:45 AM - 12:00 PM Central Time
    2688: Single cell RNA-seq immune profiling of blood samples from a psoriatic disease clinical trial reveals a CD4 T cell population associated with response to IL-23 blockade
    Location: W181A-C
    Presenting Author: Kathryne Marks, PhD – Brigham and Women's Hospital
  • Wednesday, Oct 29th
    12:00 PM - 12:15 PM Central Time
    2689: Comparison of Incidence of Psoriatic Arthritis in Patients With Psoriasis Treated With Interleukin-17 Inhibitors vs Interleukin-23 Inhibitors, Interleukin-12/23 Inhibitors, and Tumor Necrosis Factor Inhibitors in Real-World Practice: A Retrospective Study
    Location: W181A-C
    Presenting Author: April Armstrong, MD, MPH – University of California Los Angeles
  • Wednesday, Oct 29th
    12:15 PM - 12:30 PM Central Time
    2690: Dietary interventions in Psoriatic Arthritis: A Randomized controlled clinical trial
    Location: W181A-C
    Presenting Author: Lihi Eder, MD, PhD – University of Toronto
  • Wednesday, Oct 29th
    12:30 PM - 12:45 PM Central Time
    2691: Understanding the Impact of Overweight and Obesity on Treatment Response in Psoriatic Arthritis: Results from a Longitudinal Cohort Study
    Location: W181A-C
    Presenting Author: Fadi Kharouf, MD – Hadassah Medical Center - Toronto Western Hospital
  • Wednesday, Oct 29th
    12:45 PM - 1:00 PM Central Time
    2692: Individualized Strength, Mobility and Aerobic Rehabilitation Training in axial Spondyloarthritis (iSMART in axSpA)
    Location: W181A-C
    Presenting Author: Sophie De Mits, PhD, PT (she/her/hers) – Ghent University Hospital